Mangoceuticals, Inc. Common Stock (MGRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Mangoceuticals, Inc. Common Stock (MGRX) has a cash flow conversion efficiency ratio of -0.021x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-260.51K) by net assets ($12.52 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Mangoceuticals, Inc. Common Stock stock valuation for the company's overall valuation and market capitalisation.
Mangoceuticals, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Mangoceuticals, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Mangoceuticals, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mangoceuticals, Inc. Common Stock ranked by their cash flow conversion efficiency. See Mangoceuticals, Inc. Common Stock (MGRX) cash flow to debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Express Transindo Utama Tbk
JK:TAXI
|
0.008x |
|
Federal International Holdings Bhd
KLSE:8605
|
-0.049x |
|
Osmosun SA
PA:ALWTR
|
138.991x |
|
Taranis Resources Inc
V:TRO
|
-0.019x |
|
Sharc International Systems
F:IWIA
|
0.409x |
|
Exicure Inc
NASDAQ:XCUR
|
-0.908x |
|
Kesla Oyj A
HE:KELAS
|
0.068x |
|
Asmallworld AG
SW:ASWN
|
0.480x |
Annual Cash Flow Conversion Efficiency for Mangoceuticals, Inc. Common Stock (2021–2025)
The table below shows the annual cash flow conversion efficiency of Mangoceuticals, Inc. Common Stock from 2021 to 2025. View Mangoceuticals, Inc. Common Stock stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $15.20 Million | $-5.85 Million | -0.385x | -10.36% |
| 2024-12-31 | $13.95 Million | $-4.86 Million | -0.349x | +96.14% |
| 2023-12-31 | $774.75K | $-7.00 Million | -9.032x | -311.86% |
| 2022-12-31 | $614.03K | $-1.35 Million | -2.193x | -309.28% |
| 2021-12-31 | $-16.72K | $-17.52K | 1.048x | -- |
About Mangoceuticals, Inc. Common Stock
Mangoceuticals, Inc. engages in the development, marketing, and sale of various men's wellness products and services through a telemedicine platform in the United States. The company offers erectile dysfunction products under the Mango brand; hair loss products under the Grow brand; hormone balance and therapy products under the Mojo brand; and weight loss products under the Slim brand. It also p… Read more